Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
9 papers
Recent·Most cited
C. Pham-Danis, S. B. Chia, H. A. Scarborough, E. Danis, T. Nemkov, E. K. Kleczko, A. Navarro, A. Goodspeed, E. A. Bonney, C. A. Dinarello, C. Marchetti, R. A. Nemenoff, K. A. Hansen, J. DeGregori
This study investigates how aging-related inflammation contributes to lung cancer development by analyzing gene expression data and using mouse models to assess the role of inflammation in oncogenesis.
bioRxiv · Mar 1, 2024Cancer Biology
A. Goodspeed, A. Bodlak, A. B. Duffy, S. Nelson-Taylor, N. Oike, R. Shirai, D. Walker, T. E. Porfilio, A. Treece, J. O. Black, N. Donaldson, C. Cost, T. Garrington, B. Greffe, S. Luna-Fineman, , M. Hayashi
This study uses single-cell RNA-sequencing to analyze transcriptional heterogeneity in Ewing sarcoma and identifies TSPAN8 as a novel therapeutic target.
bioRxiv · Jan 18, 2024 · PreprintCancer Biology
A. M. Taylor, J. Sheng, P. K. S. Ng, J. M. Harder, P. Kumar, J. Y. Ahn, Y. Cao, A. M. Dzis, N. L. Jillette, A. Goodspeed, A. Bodlak, Q. Wu, M. S. Isakoff, J. George, J. D. S. Grassman, , C. C. Lau
This study identifies immunosuppressive mechanisms in osteosarcoma using single-cell and spatial transcriptomics, revealing interactions between MDSCs, T-cells, and tumor cells that promote an immunosuppressive microenvironment.
bioRxiv · Nov 1, 2023Cancer Biology
G. Vragel, K. S. Noell, A. Tseng, R. E. Kostelecky, E. A. Alexander, S. Cohen, C. Galvan, M. Dalwadi, B. D. Gomez, E. M. Medina, D. Oldenburg, A. Goodspeed, E. T. Clambey, L. F. van Dyk
This study shows that myeloid cells infected by gammaherpesvirus 68 exhibit divergent outcomes regulated by viral and host factors, with IL-4 converting restricted infection to productive replication.
bioRxiv · Jun 21, 2023 · PreprintMicrobiology
T. S. Mills, B. Kain, M. T. Burchill, E. Danis, A. Goodspeed, R. Culp-Hill, S. Ferrara, J. R. Roede, A. D'Alessandro, K. Y. King, E. M. Pietras
The paper shows hematopoietic stem cells (HSCs) in a mouse model of chronic autoimmune disease serve as a long-term reservoir for trained immunity, with macrophages derived from them exhibiting increased inflammatory activity and reduced metabolic function.
bioRxiv · May 20, 2022 · PreprintImmunology
H. J. Park, M. A. Gregory, V. Zaberezhnyy, A. Goodspeed, C. T. Jordan, J. S. Kieft, J. DeGregori
The paper shows that marrow-mediated activation of ATM and mTOR increases oxidative phosphorylation, leading to resistance in FLT3 mutant AML cells, and that combining mTOR and FLT3 inhibitors reduces tumor burden.
bioRxiv · Feb 14, 2022Cancer Biology
R. T. Jones, M. Scholtes, A. Goodspeed, M. M. Akbarzadeh, S. Mohapatra, L. E. Feldman, H. Vekony, A. Jean, C. B. Tilton, M. V. Orman, S. Romal, C. Deiter, T. W. Kan, N. Xander, S. Araki, , J. C. Costello
This study identifies NPEPPS as a driver of cisplatin resistance in bladder cancer and shows its inhibition can enhance cisplatin efficacy in preclinical models.
bioRxiv · Mar 4, 2021 · PreprintCancer Biology
K. C. Higa, A. Goodspeed, J. S. Chavez, V. Zaberezhnyy, J. L. Rabe, D. G. Tenen, E. M. Pietras, J. DeGregori
This study shows chronic IL-1β exposure selects for Cebpa-deficient HSPC by promoting myeloid differentiation and repressing stem cell programs, linking chronic inflammation to hematologic disorders.
bioRxiv · Mar 25, 2020Cancer Biology
A. Goodspeed, A. Jean, J. C. Costello
This study identifies low MSH2 protein levels as a marker of cisplatin resistance in bladder cancer using in vitro and clinical data.
bioRxiv · Jun 29, 2018 · PreprintCancer Biology